Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases - PubMed (original) (raw)

Review

. 2009 Oct;48(10):1190-6.

doi: 10.1093/rheumatology/kep199. Epub 2009 Jul 9.

Affiliations

• PMID: 19589888
• DOI: 10.1093/rheumatology/kep199

Review

Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases

Hélène Maillard-Lefebvre et al. Rheumatology (Oxford). 2009 Oct.

Abstract

The formation of advanced glycation end products (AGEs) is a result of the non-enzymatic reaction between sugars and free amino groups of proteins. AGEs, through interacting with their specific receptor for AGEs (RAGE), result in activation of pro-inflammatory states and are involved in numerous pathologic situations. The soluble form of RAGE (sRAGE) is able to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands (AGEs, HMGB1, S100 proteins). sRAGE levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, diabetes, renal failure and the aging process. The use of measuring circulating sRAGEs may prove to be a valuable vascular biomarker and in this review, we describe the implications of sRAGE in inflammation and propose that this molecule may represent a future therapeutic target in chronic inflammatory diseases.

PubMed Disclaimer

Similar articles

• Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
  Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T. Nakamura K, et al. Microvasc Res. 2008 May;76(1):52-6. doi: 10.1016/j.mvr.2007.09.004. Epub 2007 Oct 5. Microvasc Res. 2008. PMID: 18474381
• Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.
  Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Pullerits R, et al. Arthritis Res Ther. 2005;7(4):R817-24. doi: 10.1186/ar1749. Epub 2005 Apr 25. Arthritis Res Ther. 2005. PMID: 15987483 Free PMC article.
• Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
  Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X, Saito K, Uese K, Miyawaki T, Viemann D, Roth J, Foell D. Wittkowski H, et al. Arthritis Rheum. 2007 Dec;56(12):4174-81. doi: 10.1002/art.23042. Arthritis Rheum. 2007. PMID: 18050248
• Advanced glycation end product receptor-mediated cellular dysfunction.
  Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Bierhaus A, et al. Ann N Y Acad Sci. 2005 Jun;1043:676-80. doi: 10.1196/annals.1333.077. Ann N Y Acad Sci. 2005. PMID: 16037292 Review.
• RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts.
  Ramasamy R, Yan SF, Schmidt AM. Ramasamy R, et al. J Leukoc Biol. 2009 Sep;86(3):505-12. doi: 10.1189/jlb.0409230. Epub 2009 May 28. J Leukoc Biol. 2009. PMID: 19477910 Review.

Cited by

• The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study.
  Ciccocioppo R, Imbesi V, Betti E, Boccaccio V, Kruzliak P, Gallia A, Cangemi GC, Maffe GC, Vanoli A, Merante S, De Amici M, Falcone C, Klersy C, Corazza GR. Ciccocioppo R, et al. Dig Dis Sci. 2015 Aug;60(8):2327-37. doi: 10.1007/s10620-015-3619-7. Epub 2015 Mar 11. Dig Dis Sci. 2015. PMID: 25757448
• HMGB1: A Promising Therapeutic Target for Prostate Cancer.
  Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A. Gnanasekar M, et al. Prostate Cancer. 2013;2013:157103. doi: 10.1155/2013/157103. Epub 2013 May 12. Prostate Cancer. 2013. PMID: 23766911 Free PMC article.
• Advanced glycation end-products and their receptor-mediated roles: inflammation and oxidative stress.
  Younessi P, Yoonessi A. Younessi P, et al. Iran J Med Sci. 2011 Sep;36(3):154-66. Iran J Med Sci. 2011. PMID: 23358382 Free PMC article.
• Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.
  Nosaka N, Yashiro M, Yamada M, Fujii Y, Tsukahara H, Liu K, Nishibori M, Matsukawa A, Morishima T. Nosaka N, et al. Crit Care. 2015 Jun 11;19(1):249. doi: 10.1186/s13054-015-0983-9. Crit Care. 2015. PMID: 26067826 Free PMC article.
• Urinary excretion of amino acids and their advanced glycation end-products (AGEs) in adult kidney transplant recipients with emphasis on lysine: furosine excretion is associated with cardiovascular and all-cause mortality.
  Baskal S, Post A, Kremer D, Bollenbach A, Bakker SJL, Tsikas D. Baskal S, et al. Amino Acids. 2021 Nov;53(11):1679-1693. doi: 10.1007/s00726-021-03091-8. Epub 2021 Oct 24. Amino Acids. 2021. PMID: 34693489 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database